Research Article

Probucol-bile acid based nanoparticles protect auditory cells from oxidative stress: an in vitro study

The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Perth, Western Australia, Australia

Search for more papers by this author

Bozica Kovacevic

https://orcid.org/0000-0002-9359-7840

The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Perth, Western Australia, Australia

Search for more papers by this author

Corina Mihaela Ionescu

https://orcid.org/0000-0002-8966-0448

The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Perth, Western Australia, Australia

Search for more papers by this author

Thomas Foster

https://orcid.org/0000-0003-1779-0785

The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Perth, Western Australia, Australia

Search for more papers by this author

Melissa Jones

https://orcid.org/0000-0002-2771-1158

The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Perth, Western Australia, Australia

Search for more papers by this author

Momir Mikov

https://orcid.org/0000-0002-2804-0624

Department of Pharmacology, Toxicology & Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad (Hajduk Veljkova 3, 21101), Serbia

Search for more papers by this author

Andrew Wise

https://orcid.org/0000-0001-9715-8784

The Bionics Institute, Melbourne, Australia

Search for more papers by this author

Armin Mooranian

*Author for correspondence: Tel.: +61 8 9266 1318;

E-mail Address: a.mooranian@curtin.edu.au

^†Authors contributed equally

https://orcid.org/0000-0001-7103-2067

The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Perth, Western Australia, Australia

School of Pharmacy, University of Otago, Dunedin, Otago, New Zealand

Search for more papers by this author

Hani Al-Salami

**Author for correspondence: Tel.: +61 8 9266 9816;

E-mail Address: hani.al-salami@curtin.edu.au

^†Authors contributed equally

https://orcid.org/0000-0003-0049-6969

The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Perth, Western Australia, Australia

Medical School, University of Western Australia, Perth, Western Australia, Australia

Search for more papers by this author

Published Online:12 Mar 2024https://doi.org/10.4155/tde-2023-0099

View article

Abstract

Aim: Excessive free radicals contribute to oxidative stress and mitochondrial dysfunction in sensorineural hearing loss (SNHL). The antioxidant probucol holds promise, but its limited bioavailability and inner ear barriers hinder effective SNHL treatment. Methodology: We addressed this by developing probucol-loaded nanoparticles with polymers and lithocholic acid and tested them on House Ear Institute-Organ of Corti cells. Results: Probucol-based nanoparticles effectively reduced oxidative stress-induced apoptosis, enhanced cellular viability, improved probucol uptake and promoted mitochondrial function. Additionally, they demonstrated the capacity to reduce reactive oxygen species through the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway. Conclusion: This innovative nanoparticle system holds the potential to prevent oxidative stress-related hearing impairment, providing an effective solution for SNHL.

Plain language summary

Hearing loss affects millions of people worldwide, and its prevalence is expected to double by 2050. Current treatments have limitations, pushing researchers to explore new options. Oxidative stress is a key player in hearing loss and is known to damage inner ear hair cells. While antioxidants, known for their protective effects, hold promise, delivering them effectively to the inner ear is challenging. Scientists have been testing nanoparticles loaded with the antioxidant probucol to fight hearing loss. In this study, these particles protected inner ear cells in cell studies, offering potential hope for preventing hearing problems. This research is a significant step toward finding better treatments for hearing loss.

Graphical abstract

Keywords:

References

1. Chandrasekhar SS, Tsai Do BS, Schwartz SR et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol. Head Neck Surg. 161(Suppl. 1), S1–S45 (2019).
MedlineGoogle Scholar
2. Olusanya BO, Davis AC, Hoffman HJ. Hearing loss grades and the International classification of functioning, disability and health. Bull. World Health Organ. 97(10), 725 (2019).
MedlineGoogle Scholar
3. Olusanya BO, Neumann KJ, Saunders JE. The global burden of disabling hearing impairment: a call to action. Bull. World Health Organ. 92(5), 367–373 (2014).
MedlineGoogle Scholar
4. Pang J, Xiong H, Lin P et al. Activation of miR-34a impairs autophagic flux and promotes cochlear cell death via repressing ATG9A: implications for age-related hearing loss. Cell Death Dis. 8(10), e3079 (2017).
MedlineGoogle Scholar
5. Lee YY, Kim YJ, Gil ES, Kim H, Jang JH, Choung Y-H. Type 1 diabetes induces hearing loss: functional and histological findings in an Akita mouse model. Biomedicines 8(9), 343 (2020).
Medline CASGoogle Scholar
6. Ohinata Y, Miller JM, Schacht J. Protection from noise-induced lipid peroxidation and hair cell loss in the cochlea. Brain Res. 966(2), 265–273 (2003).
Medline CASGoogle Scholar
7. Benkafadar N, François F, Affortit C et al. ROS-induced activation of DNA damage responses drives senescence-like state in postmitotic cochlear cells: implication for hearing preservation. Mol. Neurobiol. 56(8), 5950–5969 (2019).
Medline CASGoogle Scholar
8. Baker K, Staecker H. Low dose oxidative stress induces mitochondrial damage in hair cells. Anatom. Record 295(11), 1868–1876 (2012).
CASGoogle Scholar
9. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis 207(1), 16–23 (2009).
Medline CASGoogle Scholar
10. Tanous D, Hime N, Stocker R. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. Redox. Rep. 13(2), 48–59 (2008).
Medline CASGoogle Scholar
11. Yamamoto A. A uniqe antilipidemic drug–probucol. J. Atheroscler. Thromb. 15(6), 304–305 (2008).
MedlineGoogle Scholar
12. Endo K, Miyashita Y, Sasaki H et al. Probucol delays progression of diabetic nephropathy. Diabetes Res. Clin. Pract. 71(2), 156–163 (2006).
Medline CASGoogle Scholar
13. Kondo S, Shimizu M, Urushihara M et al. Addition of the antioxidant probucol to angiotensin II Type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat. J. Am. Soc. Nephrol. 17(3), 783–794 (2006).
Medline CASGoogle Scholar
14. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Dhaliwal SS, Mamo JC. Probucol prevents blood-brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding. Clin. Exp. Pharmacol. Physiol. 40(1), 45–52 (2013).
Medline CASGoogle Scholar
15. Ribeiro RP, Moreira ELG, Santos DB et al. Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease. Neurochem. Res. 38(3), 660–668 (2013).
Medline CASGoogle Scholar
16. Santos DB, Peres KC, Ribeiro RP et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice. Exp. Neurol. 233(2), 767–775 (2012).
Medline CASGoogle Scholar
17. Heel R, Brogden R, Speight T, Avery G. Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia. Drugs 15(6), 409–428 (1978).
Medline CASGoogle Scholar
18. Wagle SR, Kovacevic B, Walker D et al. Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies. Exp. Opin. Drug Deliv. 17(10), 1361–1376 (2020).
Medline CASGoogle Scholar
19. Mooranian A, Raj Wagle S, Kovacevic B et al. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scient. Rep. 10(1), 106 (2020).
Medline CASGoogle Scholar
20. Wagle SR, Walker D, Kovacevic B et al. Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies. Scient. Rep. 10(1), 7715 (2020).
Medline CASGoogle Scholar
21. Wagle SR, Kovacevic B, Walker D et al. Pharmacological and advanced cell respiration effects, enhanced by toxic human-bile nano-pharmaceuticals of probucol cell-targeting formulations. Pharmaceutics 12(8), 708 (2020).
Medline CASGoogle Scholar
22. Wagle SR, Kovacevic B, Ionescu CM et al. Pharmacological and biological study of microencapsulated probucol-secondary bile acid in a diseased mouse model. Pharmaceutics 13(8), 1223 (2021).
Medline CASGoogle Scholar
23. Mooranian A, Ionescu CM, Walker D et al. Single-cellular biological effects of cholesterol-catabolic bile acid-based nano/micro capsules as anti-inflammatory cell protective systems. Biomolecules 12(1) 19 (2022).
Google Scholar
24. Mooranian A, Negrulj R, Chen-Tan N, Watts GF, Arfuso F, Al-Salami H. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Design, Develop. Ther. 8, 1673 (2014).
Medline CASGoogle Scholar
25. Mooranian A, Negrulj R, Mathavan S et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharmaceut. Develop. Technol. 20(6), 702–709 (2015).
Medline CASGoogle Scholar
26. Mooranian A, Negrulj R, Takechi R, Mamo J, Al-Sallami H, Al-Salami H. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv. Translat. Res. 8(3), 543–551 (2018).
Medline CASGoogle Scholar
27. Carey L, Walker D, Jones M et al. Bile acid permeation enhancement for inner ear cochlear drug pharmacological uptake: bio-nanotechnologies in chemotherapy-induced hearing loss. Therapeut. Deliv. 12(12), 807–819 (2021).
CASGoogle Scholar
28. Kovacevic B, Jones M, Ionescu C et al. The emerging role of bile acids as critical components in nanotechnology and bioengineering: pharmacology, formulation optimizers and hydrogel-biomaterial applications. Biomaterials 283, 121459 (2022).
Medline CASGoogle Scholar
29. Kasai S, Mimura J, Ozaki T, Itoh K. Emerging regulatory role of Nrf2 in iron, heme, and hemoglobin metabolism in physiology and disease. Front. Vet. Sci. 5, 242 (2018).
MedlineGoogle Scholar
30. Zhou Z, Liu C, Chen S et al. Activation of the Nrf2/ARE signaling pathway by probucol contributes to inhibiting inflammation and neuronal apoptosis after spinal cord injury. Oncotarget 8(32), 52078–52093 (2017).
MedlineGoogle Scholar
31. Szeto B, Chiang H, Valentini C, Yu M, Kysar JW, Lalwani AK. Inner ear delivery: challenges and opportunities. Laryngosc. Investig. Otolaryngol. 5(1), 122–131 (2019).
MedlineGoogle Scholar
32. Yang K-J, Son J, Jung SY et al. Optimized phospholipid-based nanoparticles for inner ear drug delivery and therapy. Biomaterials 171, 133–143 (2018).
Medline CASGoogle Scholar
33. Lajud SA, Nagda DA, Qiao P et al. A novel chitosan-hydrogel-based nanoparticle delivery system for local inner ear application. Otol. Neurotol. 36(2), 341 (2015).
MedlineGoogle Scholar
34. Pyykkö I, Zou J, Schrott-Fischer A, Glueckert R, Kinnunen P. An overview of nanoparticle based delivery for treatment of inner ear disorders. Audit. Vestib. Res. 1427, 363–415 (2016).
CASGoogle Scholar
35. Mondalek FG, Zhang YY, Kropp B et al. The permeability of SPION over an artificial three-layer membrane is enhanced by external magnetic field. J. Nanobiotechnol. 4(1), 1–9 (2006).
MedlineGoogle Scholar
36. Cai H, Wen X, Wen L et al. Enhanced local bioavailability of single or compound drugs delivery to the inner ear through application of PLGA nanoparticles via round window administration. Int. J. Nanomed. 9, 5591–5601 (2014).
MedlineGoogle Scholar
37. Wagle SR, Ionescu CM, Kovacevic B et al. Pharmaceutical characterization of probucol bile acid-lithocholic acid nanoparticles to prevent chronic hearing related and similar cellular oxidative stress pathologies. Nanomedicine 18(12), 923–940 (2023).
Medline CASGoogle Scholar
38. Mooranian A, Jones M, Ionescu CM et al. Advancements in assessments of bio-tissue engineering and viable cell delivery matrices using bile acid-based pharmacological biotechnologies. Nanomaterials 11(7), 1861 (2021).
Medline CASGoogle Scholar
39. Mooranian A, Foster T, Ionescu CM et al. Enhanced bilosomal properties resulted in optimum pharmacological effects by increased acidification pathways. Pharmaceutics 13(8), 1184 (2021).
Medline CASGoogle Scholar
40. Kovacevic B, Ionescu CM, Wagle SR et al. Impact of novel teflon-DCA nanogel matrix on cellular bioactivity. J. Pharm. Sci. 112(3), 700–707 (2022).
MedlineGoogle Scholar
41. Kalinec GM, Park C, Thein P, Kalinec F. Working with auditory HEI-OC1 cells. J. Vis. Exp. doi: 10.3791/54425 (2016).
MedlineGoogle Scholar
42. Wu J, Ye J, Kong W, Zhang S, Zheng Y. Programmed cell death pathways in hearing loss: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 53(11), e12915 (2020).
Medline CASGoogle Scholar
43. Tan WJT, Song L. Hearing research special issue: mitochondrial function and dysfunction in the inner ear. Hear. Res. 434, 108783 (2023).
MedlineGoogle Scholar
44. He RR, Li Y, Li XD et al. A new oxidative stress model, 2,2-azobis(2-amidinopropane) dihydrochloride induces cardiovascular damages in chicken embryo. PLOS ONE 8(3), e57732 (2013).
Medline CASGoogle Scholar
45. Zimowska W, Motyl T, Skierski J et al. Apoptosis and Bcl-2 protein changes in L1210 leukaemic cells exposed to oxidative stress. Apoptosis 2(6), 529–539 (1997).
Medline CASGoogle Scholar
46. Ehret G, Frankenreiter M. Quantitative analysis of cochlear structures in the house mouse in relation to mechanisms of acoustical information processing. J. Comp. Physiol. 122, 65–85 (1977).
Google Scholar
47. Fujimoto C, Yamasoba T. Oxidative stresses and mitochondrial dysfunction in age-related hearing loss. Oxid. Med. Cell. Longev. 2014, 582849 (2014).
MedlineGoogle Scholar
48. Li P, Li S, Wang L et al. Mitochondrial dysfunction in hearing loss: oxidative stress, autophagy and NLRP3 inflammasome. Front. Cell Developm. Biol. 11, 1119773 (2023).
MedlineGoogle Scholar
49. Circu ML, Aw TY. Glutathione and modulation of cell apoptosis. Biochim. et Biophys. Acta (BBA) – Molecular Cell Research 1823(10), 1767–1777 (2012).
Medline CASGoogle Scholar
50. Pallepati P, Averill-Bates D. Mild thermotolerance induced at 40°C increases antioxidants and protects HeLa cells against mitochondrial apoptosis induced by hydrogen peroxide: role of p53. Arch. Biochem. Biophys. 495(2), 97–111 (2010).
Medline CASGoogle Scholar
51. Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signaling pathways by reactive oxygen species. Biochim. Biophys. Acta 1863(12), 2977–2992 (2016).
Medline CASGoogle Scholar
52. Twiddy D, Cain K. Caspase-9 cleavage, do you need it? Biochem. J. 405(1), e1–e2 (2007).
Medline CASGoogle Scholar
53. Luna-Vargas MP, Chipuk JE. Physiological and pharmacological control of BAK, BAX, and beyond. Trend. Cell Biol. 26(12), 906–917 (2016).
Medline CASGoogle Scholar
54. Martinou J-C, Youle Richard J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Developmen. Cell 21(1), 92–101 (2011).
Medline CASGoogle Scholar
55. Honkura Y, Matsuo H, Murakami S et al. NRF2 is a key target for prevention of noise-induced hearing loss by reducing oxidative damage of cochlea. Scient. Rep. 6(1), 19329 (2016).
Medline CASGoogle Scholar
56. Honkura Y, Matsuo H, Murakami S et al. NRF2 is a key target for prevention of noise-induced hearing loss by reducing oxidative damage of cochlea. Scient. Rep. 6(1), 1–12 (2016).
MedlineGoogle Scholar
57. Cazanave S, Berson A, Haouzi D et al. High hepatic glutathione stores alleviate Fas-induced apoptosis in mice. J. Hepatol. 46(5), 858–868 (2007).
Medline CASGoogle Scholar
58. Reinehr R, Becker S, Eberle A, Grether-Beck S, Häussinger D. Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis*. J. Biol. Chem. 280(29), 27179–27194 (2005).
Medline CASGoogle Scholar
59. Matsumaru K, Ji C, Kaplowitz N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology 37(6), 1425–1434 (2003).
Medline CASGoogle Scholar
60. Takeya R, Ueno N, Kami K et al. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases*. J. Biol. Chem. 278(27), 25234–25246 (2003).
Medline CASGoogle Scholar
61. Thompson JA, Franklin CC. Enhanced glutathione biosynthetic capacity promotes resistance to As3+-induced apoptosis. Toxicol. Lett. 193(1), 33–40 (2010).
Medline CASGoogle Scholar
62. Lluis JM, Morales A, Blasco C et al. Critical role of mitochondrial glutathione in the survival of hepatocytes during hypoxia*. J. Biol. Chem. 280(5), 3224–3232 (2005).
Medline CASGoogle Scholar
63. Yamasoba T, Nuttall AL, Harris C, Raphael Y, Miller JM. Role of glutathione in protection against noise-induced hearing loss. Brain Res. 784(1–2), 82–90 (1998).
Medline CASGoogle Scholar
64. Hu BH, Zheng XY, McFadden SL, Kopke RD, Henderson D. R-phenylisopropyladenosine attenuates noise-induced hearing loss in the chinchilla. Hear Res. 113(1–2), 198–206 (1996).
Google Scholar
65. Vitale N, Kisslinger A, Paladino S et al. Resveratrol couples apoptosis with autophagy in UVB-irradiated HaCaT cells. PLOS ONE 8(11), e80728 (2013).
MedlineGoogle Scholar
66. Hosokawa K, Hosokawa S, Ishiyama G, Ishiyama A, Lopez IA. Immunohistochemical localization of Nrf2 in the human cochlea. Brain Res. 1700, 1–8 (2018).
Medline CASGoogle Scholar
67. Zhang W, Xiong H, Pang J et al. Nrf2 activation protects auditory hair cells from cisplatin-induced ototoxicity independent on mitochondrial ROS production. Toxicol. Lett. 331, 1–10 (2020).
Medline CASGoogle Scholar
68. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284(20), 13291–13295 (2009).
Medline CASGoogle Scholar
69. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59(4), 850–860 (2010).
Medline CASGoogle Scholar
70. Kong L, Chen G-D, Zhou X, McGinnis JF, Li F, Cao W. Molecular mechanisms underlying cochlear degeneration in the tubby mouse and the therapeutic effect of sulforaphane. Neurochem. Int. 54(3), 172–179 (2009).
Medline CASGoogle Scholar
71. Hoshino T, Tabuchi K, Nishimura B et al. Protective role of Nrf2 in age-related hearing loss and gentamicin ototoxicity. Biochem. Biophys. Res. Commun. 415(1), 94–98 (2011).
Medline CASGoogle Scholar
72. Li D, Zhao H, Cui Z-K, Tian G. The role of Nrf2 in hearing loss. Front. Pharmacol. 12, 620921 (2021).
Medline CASGoogle Scholar
73. Wang X, Zeng C, Lai Y et al. NRF2/HO-1 pathway activation by ATF3 in a noise-induced hearing loss murine model. Arch. Biochem. Biophys. 721, 109190 (2022).
Medline CASGoogle Scholar
74. Huang J-L, Yu C, Su M et al. Probucol, a “non-statin” cholesterol-lowering drug, ameliorates D-galactose induced cognitive deficits by alleviating oxidative stress via Keap1/Nrf2 signaling pathway in mice. Aging 11(19), 8542 (2019).
Medline CASGoogle Scholar
75. Zhongping C, Li C, Ai S, Zhou X. Effects of probucol on high glucose-induced expressions of SP1/Keap1/Nrf2/GCLC in the cultured human Müller cells. Investig. Ophthalmol. Vis. Sci. 60(9), 5368 (2019).
Google Scholar
76. Wang H, Zhang K, Ruan Z et al. Probucol enhances the therapeutic efficiency of mesenchymal stem cells in the treatment of erectile dysfunction in diabetic rats by prolonging their survival time via Nrf2 pathway. Stem Cell Res. Ther. 11(1), 302 (2020).
MedlineGoogle Scholar
77. Abe H, Arai H, Sakurai A, Yamashita K, Murayama T, Minami M. Probucol modulates Nrf2 function and ameliorates diabetic nephropathy in db/db mice. Med. Res. Archiv. 4(8), (2016).
Google Scholar

Vol. 15, No. 4

Metrics

Downloaded 15 times

History

Received 9 October 2023

Accepted 9 February 2024

Published online 12 March 2024

Published in print April 2024

Information

Keywords

Author contributions

Conceptualization, H Al-Salami, M Mikov, A Mooranian and A Wise; Data curation S Raj Wagle, CM Ionescu, B Kovacevic, M Jones and T Foster; funding acquisition, H Al-Salami, M Mikov and A Mooranian; investigation, all authors; methodology, S. Raj Wagle, CM Ionescu, B Kovacevic, M Jones, T Foster; project administration, H Al-Salami, M Mikov, A Mooranian and A Wise; resources, H Al-Salami, M Mikov, A Mooranian and A Wise; supervision, H Al-Salami, M Mikov, A Mooranian and A Wise; validation, S Raj Wagle, CM Ionescu, B Kovacevic, M Jones, T Foster and; visualization, S Raj Wagle, CM Ionescu, B Kovacevic, M Jones, T Foster; writing-original draft, S Raj Wagle; writing-review & editing, all authors. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

The authors acknowledge the Australian Research Training Program Scholarship for their support, Mr. Michael Nesbit from the Confocal Curtin Health Innovation Research Institute Microscopy for assistance with Andor Dragonfly supported by the Australian Research Council – LIEF LE200100122. The authors are very grateful to YJ Seo (Yonsei University Wonju College of Medicine) and F Kalinec (UCLA) for the auditory cells.

Financial disclosure

Curtin Faculty ORS-WAHAI Consortium, the Australian National Health and Medical Research (APP9000597) partially support this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

H Al-Salamiis currently receiving funding from Austin Biotec Pty, Ltd and Glanis PTY Ltd. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Edboard disclosure

H Al Salami is a member of the Therapeutic Delivery Editorial Board. They were not involved in any editorial decisions related to the publication of this article, and all author details were blinded to the article's peer reviewers as per the journal's double-blind peer review policy.

Data availability

All data is available upon request to the corresponding author.

PDF download